RLFTY (MindMaze Therapeutics Holding) Research & Development: $ Mil (TTM As of Dec. 2025)


RLFTY MindMaze Therapeutics Holding SA RLFTY
11 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Research & Development?

MindMaze Therapeutics Holding RLFTY 11 Research & Development is $ Mil as of Dec. 2025. GuruFocus rates RLFTY with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MindMaze Therapeutics Holding's Research & Development for the six months ended in Dec. 2025 was $6.64 Mil. MindMaze Therapeutics Holding does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2025.

MindMaze Therapeutics Holding  (OTCPK:RLFTY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MindMaze Therapeutics Holding Research & Development Related Terms

MindMaze Therapeutics Holding Research & Development Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Research & Development Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Research & Development
0.00 6.64

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Research & Development 0.00 6.64
RLFTY
11GF Score
MindMaze Therapeutics Holding SA RLFTY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $ Mil mean?
MindMaze Therapeutics Holding (RLFTY) has a Research & Development of $ Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's Research & Development too high?
MindMaze Therapeutics Holding's current Research & Development is $ Mil. Overall, MindMaze Therapeutics Holding has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Research & Development compare to VRTX and REGN?
MindMaze Therapeutics Holding's Research & Development of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Research & Development is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (RLFTY) has a current Research & Development of $ Mil. The current Research & Development is $ Mil. MindMaze Therapeutics Holding's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MindMaze Therapeutics Holding (RLFTY), the current Research & Development is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges MMTXz:UKMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score

Get the complete analysis for RLFTY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price